Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McNeil sales

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson's McNeil division's fourth-quarter sales were flat, the firm reports in Jan. 24 fourth-quarter/year-end call. The shift of consumer products sold overseas such asPepcid and Imodium from the pharma division to McNeil offset a 4% drop in sales that was mainly due to state and retail restrictions on the sale of pseudoephedrine, J&J said. The firm reclassified the products in January 2005 (1"The Tan Sheet" July 25, 2005, p. 10). Full-year consumer segment sales grew 9% to $9 bil....

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts